Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients

被引：6

作者：

Liu, Anthony P. Y. ^{[1
,2
,3
]}

Smith, Kyle S. ^{[3
]}

Kumar, Rahul ^{[3
,4
]}

Robinson, Giles W. ^{[5
]}

Northcott, Paul A. ^{[3
]}

机构：

[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China

[2] Hong Kong Childrens Hosp, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China

[3] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Div Brain Tumor Res, Memphis, TN 38105 USA

[4] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA

[5] St Jude Childrens Res Hosp, Dept Oncol, Div Neurooncol, Memphis, TN 38105 USA

来源：

STAR PROTOCOLS | 2022年 / 3卷 / 02期

关键词：

SERIAL ASSESSMENT; DISEASE;

D O I：

10.1016/j.xpro.2022.101292

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

This protocol summarizes the pipeline for analysis of tumor-derived cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) using low-coverage whole-genome sequencing (lcWGS). This approach enables resolution of chromosomal and focal copy-number variations (CNVs) as oncologic signatures, particularly for patients with central nervous system tumors. Our strategy tolerates sub-nanogram cfDNA input and is thus optimized for CSF samples where cfDNA yields are typically low. Overall, the detection of tumor-specific signatures in CSF-derived cfDNA is a promising biomarker for personalization of brain-tumor therapy.For complete details on the use and execution of this protocol, please refer to Liu et al. (2021).

引用

页数：13